HeartcoR Solutions, a leading ECG core lab that conducts cardiac safety studies for the pharmaceutical, medical device, and CRO industries, announced today that it has partnered with Wellysis, a leading digital healthcare company specializing in wearable electrocardiogram (ECG) technology, for exclusive rights to use the Wellysis S-Patch device in clinical trials.

Cardiac safety trials are essential to the development and commercialization of a wide variety of medical devices, medical procedures, pharmaceuticals, and everyday products like dermatology products and over-the-counter medications. However, compliance and completion by participants can influence clinical outcomes. By delivering remote monitoring devices – like the Wellysis S-Patch – that are easy for participants to use and wear with minimal disruption to their daily lives, but that also capture and transmit consistently accurate ECG data, HeartcoR Solutions improves the clinical trial outcomes for healthcare companies and participants. As a result of this partnership, HeartcoR Solutions has the exclusive rights to offer the S-Patch to its partners to be used in global clinical trials.

Ciaran Cooper, CEO of HeartcoR Solutions commented:

“This is an exciting milestone in our continued growth. Partnering with Wellysis brings significant benefits to our company and our customers, offering an innovative and cost-effective new technology that will directly enhance the services we provide. With the addition of the S-Patch and our exclusive partnership with Wellysis, we continue to expand our capabilities in remote safety monitoring.”

The Wellysis FDA-cleared ExL model S-Patch, a state-of-the-art cardiac monitor, is designed specifically for extended testing periods of up to 14 days on a single battery charge. Weighing only 9g, the S-Patch is a small and lightweight wearable device that minimizes noise while accurately collecting ECG waveforms, resulting in a high detection rate for arrhythmias. The S-Patch is waterproof and comfortable to wear, providing ease of use during routine daily activities – ideally suited for patient-centric clinical trials.

“This collaboration leverages our FDA-cleared ExL model S-Patch – the world’s most advanced continuous ECG wearable,” said Young Juhn, CEO of Wellysis. “Purpose-built for extended testing, it delivers unmatched signal fidelity in an ultra-light, virtually imperceptible, waterproof, and reusable form factor. Operating for weeks on a single charge and enabling rapid turnaround within minutes, the S-Patch integrates seamlessly with industry-trusted electrodes, ensuring compliance, clinical insights, operational efficiency, and trial outcomes.”